Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Wat is de waarde van uniQure?
Volgen
@Pim Als in: Sanofi->Crucell per.c6 influenza. Wat een naaistreek was dat.
flosz schreef op 13 juni 2019 16:11 :
@Pim
Als in: Sanofi->Crucell per.c6 influenza.
Wat een naaistreek was dat.
Echt prima voorbeeld, dat was powerplay en ik denk dat je niet kan uitsluiten dat pharma-bonzen (nog steeds of alweer) zo denken.
$BLUE Zynteglo price announcement made as part of their presentation at EHA today, slide 35; commercial launch details at slide 29: investor.bluebirdbio.com/static-files... twitter.com/alliancerm/status/1139531... We’re committed to paving the way for a new payment model - but we can’t do it alone. Together, let’s #RecodeTheSystem twitter.com/bluebirdbio/status/113951...
ben benieuwd wat ze op de jaarvergadering over prijsstelling te melden hebben...
Gene-Therapy Firm UniQure Explores Options Including Sale UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said. The biotechnology company is working with advisers as it weighs options including a sale or partnerships, according to the people, who asked not to be identified because the information is private. UniQure’s shares have risen 151% in U.S. trading this year, giving it a market value of about $2.7 billion. Major pharmaceutical firms have been pursuing gene-therapy companies that promise to treat rare, debilitating diseases by correcting DNA flaws. While the field has yet to deliver a blockbuster, the promise of dramatic cures carrying multimillion-dollar price tags has triggered a flurry of deal activity. Cantor Fitzgerald LP said in February that UniQure “could be next” and may attract interest from large-cap companies such as Novo Nordisk A/S, Pfizer Inc. and Sanofi. A deal with UniQure would bring access to a pipeline of experimental treatments for hemophilia, Huntington’s disease and other disorders. The company is incorporated in the Netherlands, with about 200 employees spread between Amsterdam and Lexington, Massachusetts, according to its website. Read more: After $1 Million Drug Flop, UniQure Revives in Gene Therapy No final decisions have been made, and there’s no certainty the deliberations will lead to a transaction, the people said. A representative for UniQure declined to comment. Biogen Inc. agreed earlier this year to buy Nightstar Therapeutics Plc, and Pfizer Inc. bought a stake in Vivet Therapeutics. Roche Holding AG agreed in February to acquire Spark Therapeutics Inc. for $4.8 billion, following Novartis AG’s $8.7 billion purchase of AveXis Inc. last year. UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn’t renew its marketing authorization in 2017. Since then, the company has focused on hemophilia treatments.www.bloomberg.com/amp/news/articles/2...
flosz schreef op 16 juni 2019 17:35 :
Gene-Therapy Firm UniQure Explores Options Including Sale
UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said.
Wow. Dit is niet zo maar een gerucht. Bij zo'n proces zijn zoveel partijen betrokken dat een lek bijna onvermijdelijk is. Eens zien wat dat met de koers doet morgen.
Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report All the enthusiasm that’s been whipped up in the gene therapy field this past year has helped stoke the rumor mill about all sorts of possibilities for uniQure $QURE, which has seen a quick run-up on its share price. And now the biotech’s backers are getting a big boost from Bloomberg to keep the run going. There’s no deal to report, but sources are telling the business news service that uniQure has brought in advisers to see what might be done — including a sale — with the pharma giants now prowling the clinical players for partners and acquisitions. Cue more excited chatter on Twitter about the possibilities. The story comes in the wake of Novartis’ $8.7 billion acquisition of AveXis, which delivered the newly approved gene therapy Zolgensma, now the highest priced therapy on the planet (for a one-time use). Bluebird may have raised more questions than they answered with its newly announced $1.8 million sticker on their first gene therapy approval, but they’ve kept things interesting. And Roche may be struggling, but it’s intent on closing their $4.3 billion Spark buyout to add gene therapy to the portfolio. UniQure started the year with a share price of $28.53. Now, close to 6 months later, it will open in the morning at $72.55, with a $2.74 billion market cap that would make it an easy bolt-on for any big player looking to either get into the game or expand the team. That said, these source-driven moves to “explore options” quite often end nowhere. UniQure has been around for 21 years and is widely followed these days for its late-stage hemophilia B gene therapy program. They don’t need to plant a ‘for sale’ sign in the yard to make it known they’re available. Just how hot is gene therapy in the deal world these days? We’ll take an in-depth look at the numbers for you early Monday.endpts.com/cue-the-ma-chatter-uniqure...
De titel van dit draadje is nu echt relevant. Wat is nu de waarde van UniQure met alle potentieel aan waardeontwikkeling de komende jaren? Zijn er onder ons die dit eerder hebben meegemaakt? Meestal bij dit soort fondsen komt er een overnamebod van een andere partij, nu biedt QniQure zichzelf aan als overname kandidaat of samenwerkingspartij.
flosz schreef op 17 juni 2019 09:25 :
Just how hot is gene therapy in the deal world these days? We’ll take an in-depth look at the numbers for you early Monday.
endpts.com/cue-the-ma-chatter-uniqure... Helaas zit dit verhaal achter een paywall :(
flosz schreef op 17 juni 2019 14:16 :
Helaas idd.
Next:
twitter.com/fiercebiotech/status/1140... Dank. Niet te geloven dat ie hem A en B door elkaar haalt.
Een overname wordt ALTIJD verwacht. Wat er nu weer speelt, is dat het aandeel een weerstand nadert, waar ik althans voor de beslissng sta, winst nemen en tevreden zijn, of toch maar weer een eventueel >>>lange>>> rit omlaag gaan meemaken, dit, omdat 200 dollar altijd aan de einder kan staan te wachten. Net zoals dat met eerdere zgn fantasie doelen het geval was, en die bewaarheid werden:) 78.27 USD +7.88% Cours en temps réel. Temps réel Cboe BZX - 17/06 14:45:32
Cours en temps réel. Temps réel Cboe BZX - 17/06 16:05:38 80.21 USD Top zetten? Overname???
Wordt in ieder geval een interessante AVA. @Izette: zou goed kunnen dat dit draadje binnen afzienbare tijd herdoopt moet worden in "wat was de waarde van uniQure" Of is het een storm in een glas water?
rationeel schreef op 17 juni 2019 16:13 :
75,55 weerstand.
Die weerstand van 75,55 is toch niet meer interessant, nu we boven de 80 staan?
rationeel schreef op 17 juni 2019 16:10 :
Gap 72,55.
Wat houdt dat precies in Rationeel?
T. Montana schreef op 17 juni 2019 16:08 :
Wordt in ieder geval een interessante AVA.
@Izette: zou goed kunnen dat dit draadje binnen afzienbare tijd herdoopt moet worden in "wat was de waarde van uniQure"
Of is het een storm in een glas water?
Nee dat denk ik niet, verwacht soortgelijk nieuws al een tijdje, vraag is volgens mij niet of, maar meer wanneer?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
861,75
-0,42%
EUR/USD
1,0661
+0,17%
FTSE 100
7.835,57
-0,53%
Germany40^
17.746,70
-0,51%
Gold spot
2.381,31
+0,08%
NY-Nasdaq Composite
15.601,50
-0,52%
Stijgers
Dalers